Peter Wilden

Peter Wilden currently works at Schlumberger GmbH, as Vice Chairman-Supervisory Board from 2014, PolyPeptide Laboratories Holding (PPL) AB, as Chairman, PolyPeptide Group AG, as Chairman from 2023, Project HOPE-The-People-To-People HealthFoundation, Inc., as Director from 2012, Ferring Laboratories Ltd., as Director from 2004, Nesos Vermögensverwaltung GmbH, as Managing Director, and Ferring GmbH, as Member-Supervisory Board.
Dr. Wilden also formerly worked at Ferring International Center SA, as Executive Chairman from 2002 to 2023, Lonza Group AG, as Director from 2010 to 2014, Aureum Realwert AG, as Director from 1999 to 2002, Ferring BV, as Director-Group Finance from 1995 to 2000, Trizell Holding SA, as Director from 2014 to 2021, Ferring Pharmaceuticals A, as Chief Financial Officer & Executive Vice President from 2013 to 2017, Krupp Mak Maschinenbau GmbH, as Management Assistant in 1988, Kiel Institute for the World Economy, as Scientific Assistant-Information Technology Group in 1986, and FERRING Arzneimittel GmbH (Germany), as VP-Finance, Accounting & Technical Operations from 1993 to 1996.
Dr. Wilden received his doctorate degree in 1991 from the University of Kiel and Masters Business Admin degree in 1986 from the University of Kiel.